Wednesday, February 10, 2010, 12:53PM AEST - The Australian Stockmarket closes in 3 hours and 12 minutes.
To create a watchlist or portfolio of shares, Register

Amicus Therapeutics, Inc. (FOLD)

 8:00AM AEST: 3.49 USD  Up 0.05 (1.45%)  
 MORE ON FOLD 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Amicus Therapeutics, Inc. (NGM:FOLD) Delayed quote dataEdit
Last Trade:3.49 USD
Trade Time: 8:00AM AEST
Change:Up 0.05 (1.45%)
Prev Close:3.44
Open:3.44
Bid:3.11 x 100
Ask:N/A
1y Target Est:3.50
Day's Range:3.43 - 3.70
52wk Range:3.21 - 13.50
Volume:36,114
Avg Vol (3m):54,101.6
Market Cap:79.04M
P/E (ttm):N/A
EPS (ttm):-2.37
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add FOLD to Portfolio   Download Data

 HEADLINES 
•Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
PR Newswire (Sat, Feb 6)
•Amicus Therapeutics to Announce Fourth Quarter and Year End 2009 Financial Results on February 16, 2010
PR Newswire (Fri, Feb 5)
•Bristol & Genzyme Make A Big Move-Call It "Extraordinary Measures"
at CNBC (Sat, Jan 23)
•Genzyme: Shire Chomping at the Bit
at Seeking Alpha (Tue, Jan 19)
•The Science Of Hollywood
at CNBC (Fri, Jan 15)
•AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 12)
•Amicus Therapeutics Outlines 2010 Strategic Priorities and Continued Progress with Product Pipeline
PR Newswire (Tue, Jan 12)
•Getting Ready For The Big One In San Francisco
at CNBC (Sat, Jan 9)
•Amicus Therapeutics to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010
PR Newswire (Wed, Jan 6)
•Biotech On The Big Screen
at CNBC (Fri, Jan 1)
•Amicus Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
PR Newswire (Fri, Nov 13)
•AMICUS THERAPEUTICS INC Financials
EDGAR Online Financials (Wed, Nov 11)
•AMICUS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Nov 5)
•AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Wed, Nov 4)
More Headlines for FOLD...
 ANALYST 
EPS Est (next year) (Dec-09) :-2.48
EPS Est (in 2 years) (Dec-10) :-2.07
Avg Rec (current)*:3.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs, known as pharmacological chaperones, for the treatment of various human genetic dise...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices